https://doi.org/10.4081/mem.2011.170

Ulipristal acetate. An emergency contraceptive?

V. 60 N. 2 (2011)
Pubblicato: aprile 30, 2011
Contraccezione d’emergenza, ulipristal acetato / Emergency contraception, ulipristal acetate
Abstract Views: 686
PDF: 3
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Autori

Justo Aznar
justo.aznar@ucv.es
Medical Doctor, Director of the Institute of Life Science of the Catholic University of Valencia, Spain.
Julio Tudela
Member of the Institute of Life Sciences of the Catholic University of Valencia, Spain.
Il forte aumento delle gravidanze e degli aborti negli adolescenti sembra giustificare l'adozione di misure per prevenirli. Sebbene la giusta soluzione al problema è senza dubbio l'educazione dei giovani ad un uso corretto della sessualità, e soprattutto in una considerazione di quest'ultima come parte fondamentale di qualcosa di molto più ampio come l'amore umano, alcuni intendono risolvere il problema implementando l'uso della contraccezione d'emergenza come unica misura contraccetiva. Uno degli ultimi farmaci in commercio per questo scopo è Ulipristal acetato, che ha cominciato ad essere distribuito in alcuni paesi europei dal novembre del 2009. Questo articolo fa riferimento alla composizione chimica di Ulipristal acetato, la sua efficacia contraccetiva, gli effetti collaterali, che non sono molto significativi, e in particolare al meccanismo d'azione con cui questo farmaco impedisce le gravidanze indesiderate, giungendo alla conclusione che per almeno il 60% del tempo esso agisce secondo un meccanismo antiimpianto, anche se ciò dipende in larga misura dal giorno in cui la donna lo assume entro il suo ciclo riproduttivo, e dal tempo trascorso dal rapporto sessuale.
----------
The large increase in pregnancies and abortions in adolescents appears to justify taking measures to prevent them. Although the right solution to the problem is undoubtedly through educating young people in the proper use of sexuality, and especially in considering it as a fundamental part of something much wider like human love, certain classes advocate resolving it by implementing the use of emergency contraception as the only contraceptive measure. One of the latest drugs marketed for this purpose is Ulipristal acetate, which began to be distributed in some European countries in November 2009. This paper refers to the chemical composition of Ulipristal acetate, its contraceptive efficacy, the side effects, which are not very significant, and especially to the mechanism of action by which this drug prevents unwanted pregnancies, concluding that at least 60% of the time it acts by an anti-implantation mechanism, although this depends to a large extent on the day on which the woman takes it, within her reproductive cycle, and on the time from sexual intercourse until she takes the drug.

Dimensions

Altmetric

PlumX Metrics

Downloads

I dati di download non sono ancora disponibili.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Come citare

Aznar, J., & Tudela, J. (2011). Ulipristal acetate. An emergency contraceptive?. Medicina E Morale, 60(2). https://doi.org/10.4081/mem.2011.170

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

An Open Access Publication is one that meets the following two conditions:

  1. the author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use.
  2. a complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other well-established organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.